img

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Research Report 2024

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
According to MRAResearch’s new survey, global Acute Respiratory Distress Syndrome (ARDS) Treatment market is projected to reach US$ 469.8 million in 2033, increasing from US$ 377.7 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Acute Respiratory Distress Syndrome (ARDS) Treatment market research.
North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Acute Respiratory Distress Syndrome (ARDS) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Gilead Sciences Inc.
Terumo Corporation
Getinge Ab
Livanova Plc
Medtronic
Alung Technologies, Inc.
Armstrong Medical
Besmed Health Business Corp.
Dragerwerk Ag & Co. Kgaa
Eurosets
F. Hoffmann-la Roche Ltd.
Fisher & Paykel Healthcare Limited
Fresenius Se & Co. Kgaa
Hamilton Medical
Nice Neotech Medical Systems Pvt.ltd.
Nipro
Pfizer Inc.
Resmed
Smiths Medical
Weinmann Emergency Medical Technology Gmbh+co. Kg
Segment by Type
Oral
Intravenous Injection
Intramuscular Injection

Segment by Application


Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Acute Respiratory Distress Syndrome (ARDS) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Oral
1.2.3 Intravenous Injection
1.2.4 Intramuscular Injection
1.3 Market by Application
1.3.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Perspective (2018-2033)
2.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Growth Trends by Region
2.2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Region (2024-2033)
2.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
2.3.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Industry Trends
2.3.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Drivers
2.3.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Challenges
2.3.4 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Revenue
3.1.1 Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Revenue (2018-2023)
3.1.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue
3.4 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Concentration Ratio
3.4.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in 2022
3.5 Acute Respiratory Distress Syndrome (ARDS) Treatment Key Players Head office and Area Served
3.6 Key Players Acute Respiratory Distress Syndrome (ARDS) Treatment Product Solution and Service
3.7 Date of Enter into Acute Respiratory Distress Syndrome (ARDS) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Type
4.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Type (2024-2033)
5 Acute Respiratory Distress Syndrome (ARDS) Treatment Breakdown Data by Application
5.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2018-2033)
6.2 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023)
6.4 North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2018-2033)
7.2 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023)
7.4 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2018-2033)
8.2 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2018-2033)
9.2 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023)
9.4 Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2018-2033)
10.2 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences Inc.
11.1.1 Gilead Sciences Inc. Company Detail
11.1.2 Gilead Sciences Inc. Business Overview
11.1.3 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.1.4 Gilead Sciences Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.1.5 Gilead Sciences Inc. Recent Development
11.2 Terumo Corporation
11.2.1 Terumo Corporation Company Detail
11.2.2 Terumo Corporation Business Overview
11.2.3 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.2.4 Terumo Corporation Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.2.5 Terumo Corporation Recent Development
11.3 Getinge Ab
11.3.1 Getinge Ab Company Detail
11.3.2 Getinge Ab Business Overview
11.3.3 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.3.4 Getinge Ab Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.3.5 Getinge Ab Recent Development
11.4 Livanova Plc
11.4.1 Livanova Plc Company Detail
11.4.2 Livanova Plc Business Overview
11.4.3 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.4.4 Livanova Plc Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.4.5 Livanova Plc Recent Development
11.5 Medtronic
11.5.1 Medtronic Company Detail
11.5.2 Medtronic Business Overview
11.5.3 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.5.4 Medtronic Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.5.5 Medtronic Recent Development
11.6 Alung Technologies, Inc.
11.6.1 Alung Technologies, Inc. Company Detail
11.6.2 Alung Technologies, Inc. Business Overview
11.6.3 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.6.4 Alung Technologies, Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.6.5 Alung Technologies, Inc. Recent Development
11.7 Armstrong Medical
11.7.1 Armstrong Medical Company Detail
11.7.2 Armstrong Medical Business Overview
11.7.3 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.7.4 Armstrong Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.7.5 Armstrong Medical Recent Development
11.8 Besmed Health Business Corp.
11.8.1 Besmed Health Business Corp. Company Detail
11.8.2 Besmed Health Business Corp. Business Overview
11.8.3 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.8.4 Besmed Health Business Corp. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.8.5 Besmed Health Business Corp. Recent Development
11.9 Dragerwerk Ag & Co. Kgaa
11.9.1 Dragerwerk Ag & Co. Kgaa Company Detail
11.9.2 Dragerwerk Ag & Co. Kgaa Business Overview
11.9.3 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.9.4 Dragerwerk Ag & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.9.5 Dragerwerk Ag & Co. Kgaa Recent Development
11.10 Eurosets
11.10.1 Eurosets Company Detail
11.10.2 Eurosets Business Overview
11.10.3 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.10.4 Eurosets Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.10.5 Eurosets Recent Development
11.11 F. Hoffmann-la Roche Ltd.
11.11.1 F. Hoffmann-la Roche Ltd. Company Detail
11.11.2 F. Hoffmann-la Roche Ltd. Business Overview
11.11.3 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.11.4 F. Hoffmann-la Roche Ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.11.5 F. Hoffmann-la Roche Ltd. Recent Development
11.12 Fisher & Paykel Healthcare Limited
11.12.1 Fisher & Paykel Healthcare Limited Company Detail
11.12.2 Fisher & Paykel Healthcare Limited Business Overview
11.12.3 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.12.4 Fisher & Paykel Healthcare Limited Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.12.5 Fisher & Paykel Healthcare Limited Recent Development
11.13 Fresenius Se & Co. Kgaa
11.13.1 Fresenius Se & Co. Kgaa Company Detail
11.13.2 Fresenius Se & Co. Kgaa Business Overview
11.13.3 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.13.4 Fresenius Se & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.13.5 Fresenius Se & Co. Kgaa Recent Development
11.14 Hamilton Medical
11.14.1 Hamilton Medical Company Detail
11.14.2 Hamilton Medical Business Overview
11.14.3 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.14.4 Hamilton Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.14.5 Hamilton Medical Recent Development
11.15 Nice Neotech Medical Systems Pvt.ltd.
11.15.1 Nice Neotech Medical Systems Pvt.ltd. Company Detail
11.15.2 Nice Neotech Medical Systems Pvt.ltd. Business Overview
11.15.3 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.15.4 Nice Neotech Medical Systems Pvt.ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.15.5 Nice Neotech Medical Systems Pvt.ltd. Recent Development
11.16 Nipro
11.16.1 Nipro Company Detail
11.16.2 Nipro Business Overview
11.16.3 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.16.4 Nipro Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.16.5 Nipro Recent Development
11.17 Pfizer Inc.
11.17.1 Pfizer Inc. Company Detail
11.17.2 Pfizer Inc. Business Overview
11.17.3 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.17.4 Pfizer Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.17.5 Pfizer Inc. Recent Development
11.18 Resmed
11.18.1 Resmed Company Detail
11.18.2 Resmed Business Overview
11.18.3 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.18.4 Resmed Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.18.5 Resmed Recent Development
11.19 Smiths Medical
11.19.1 Smiths Medical Company Detail
11.19.2 Smiths Medical Business Overview
11.19.3 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.19.4 Smiths Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.19.5 Smiths Medical Recent Development
11.20 Weinmann Emergency Medical Technology Gmbh+co. Kg
11.20.1 Weinmann Emergency Medical Technology Gmbh+co. Kg Company Detail
11.20.2 Weinmann Emergency Medical Technology Gmbh+co. Kg Business Overview
11.20.3 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Introduction
11.20.4 Weinmann Emergency Medical Technology Gmbh+co. Kg Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
11.20.5 Weinmann Emergency Medical Technology Gmbh+co. Kg Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Oral
Table 3. Key Players of Intravenous Injection
Table 4. Key Players of Intramuscular Injection
Table 5. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Region (2018-2023)
Table 9. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Region (2024-2033)
Table 11. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Trends
Table 12. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Drivers
Table 13. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Challenges
Table 14. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Restraints
Table 15. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Players (2018-2023)
Table 17. Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment as of 2022)
Table 18. Ranking of Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Acute Respiratory Distress Syndrome (ARDS) Treatment Product Solution and Service
Table 22. Date of Enter into Acute Respiratory Distress Syndrome (ARDS) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Type (2024-2033)
Table 28. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Application (2018-2023)
Table 30. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Application (2024-2033)
Table 32. North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 47. Gilead Sciences Inc. Company Detail
Table 48. Gilead Sciences Inc. Business Overview
Table 49. Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 50. Gilead Sciences Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 51. Gilead Sciences Inc. Recent Development
Table 52. Terumo Corporation Company Detail
Table 53. Terumo Corporation Business Overview
Table 54. Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 55. Terumo Corporation Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 56. Terumo Corporation Recent Development
Table 57. Getinge Ab Company Detail
Table 58. Getinge Ab Business Overview
Table 59. Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 60. Getinge Ab Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 61. Getinge Ab Recent Development
Table 62. Livanova Plc Company Detail
Table 63. Livanova Plc Business Overview
Table 64. Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 65. Livanova Plc Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 66. Livanova Plc Recent Development
Table 67. Medtronic Company Detail
Table 68. Medtronic Business Overview
Table 69. Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 70. Medtronic Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 71. Medtronic Recent Development
Table 72. Alung Technologies, Inc. Company Detail
Table 73. Alung Technologies, Inc. Business Overview
Table 74. Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 75. Alung Technologies, Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 76. Alung Technologies, Inc. Recent Development
Table 77. Armstrong Medical Company Detail
Table 78. Armstrong Medical Business Overview
Table 79. Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 80. Armstrong Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 81. Armstrong Medical Recent Development
Table 82. Besmed Health Business Corp. Company Detail
Table 83. Besmed Health Business Corp. Business Overview
Table 84. Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 85. Besmed Health Business Corp. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 86. Besmed Health Business Corp. Recent Development
Table 87. Dragerwerk Ag & Co. Kgaa Company Detail
Table 88. Dragerwerk Ag & Co. Kgaa Business Overview
Table 89. Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 90. Dragerwerk Ag & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 91. Dragerwerk Ag & Co. Kgaa Recent Development
Table 92. Eurosets Company Detail
Table 93. Eurosets Business Overview
Table 94. Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 95. Eurosets Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 96. Eurosets Recent Development
Table 97. F. Hoffmann-la Roche Ltd. Company Detail
Table 98. F. Hoffmann-la Roche Ltd. Business Overview
Table 99. F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 100. F. Hoffmann-la Roche Ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 101. F. Hoffmann-la Roche Ltd. Recent Development
Table 102. Fisher & Paykel Healthcare Limited Company Detail
Table 103. Fisher & Paykel Healthcare Limited Business Overview
Table 104. Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 105. Fisher & Paykel Healthcare Limited Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 106. Fisher & Paykel Healthcare Limited Recent Development
Table 107. Fresenius Se & Co. Kgaa Company Detail
Table 108. Fresenius Se & Co. Kgaa Business Overview
Table 109. Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 110. Fresenius Se & Co. Kgaa Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 111. Fresenius Se & Co. Kgaa Recent Development
Table 112. Hamilton Medical Company Detail
Table 113. Hamilton Medical Business Overview
Table 114. Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 115. Hamilton Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 116. Hamilton Medical Recent Development
Table 117. Nice Neotech Medical Systems Pvt.ltd. Company Detail
Table 118. Nice Neotech Medical Systems Pvt.ltd. Business Overview
Table 119. Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 120. Nice Neotech Medical Systems Pvt.ltd. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 121. Nice Neotech Medical Systems Pvt.ltd. Recent Development
Table 122. Nipro Company Detail
Table 123. Nipro Business Overview
Table 124. Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 125. Nipro Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 126. Nipro Recent Development
Table 127. Pfizer Inc. Company Detail
Table 128. Pfizer Inc. Business Overview
Table 129. Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 130. Pfizer Inc. Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 131. Pfizer Inc. Recent Development
Table 132. Resmed Company Detail
Table 133. Resmed Business Overview
Table 134. Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 135. Resmed Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 136. Resmed Recent Development
Table 137. Smiths Medical Company Detail
Table 138. Smiths Medical Business Overview
Table 139. Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 140. Smiths Medical Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 141. Smiths Medical Recent Development
Table 142. Weinmann Emergency Medical Technology Gmbh+co. Kg Company Detail
Table 143. Weinmann Emergency Medical Technology Gmbh+co. Kg Business Overview
Table 144. Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Product
Table 145. Weinmann Emergency Medical Technology Gmbh+co. Kg Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023) & (US$ Million)
Table 146. Weinmann Emergency Medical Technology Gmbh+co. Kg Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Type: 2022 VS 2033
Figure 3. Oral Features
Figure 4. Intravenous Injection Features
Figure 5. Intramuscular Injection Features
Figure 6. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Application: 2022 VS 2033
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Online Pharmacy Case Studies
Figure 11. Acute Respiratory Distress Syndrome (ARDS) Treatment Report Years Considered
Figure 12. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Region: 2022 VS 2033
Figure 15. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Players in 2022
Figure 16. Global Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Respiratory Distress Syndrome (ARDS) Treatment as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in 2022
Figure 18. North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Country (2018-2033)
Figure 20. United States Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Country (2018-2033)
Figure 24. Germany Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Region (2018-2033)
Figure 32. China Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Country (2018-2033)
Figure 40. Mexico Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Share by Country (2018-2033)
Figure 44. Turkey Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Gilead Sciences Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 47. Terumo Corporation Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 48. Getinge Ab Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 49. Livanova Plc Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 50. Medtronic Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 51. Alung Technologies, Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 52. Armstrong Medical Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 53. Besmed Health Business Corp. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 54. Dragerwerk Ag & Co. Kgaa Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 55. Eurosets Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 56. F. Hoffmann-la Roche Ltd. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 57. Fisher & Paykel Healthcare Limited Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 58. Fresenius Se & Co. Kgaa Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 59. Hamilton Medical Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 60. Nice Neotech Medical Systems Pvt.ltd. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 61. Nipro Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 62. Pfizer Inc. Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 63. Resmed Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 64. Smiths Medical Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 65. Weinmann Emergency Medical Technology Gmbh+co. Kg Revenue Growth Rate in Acute Respiratory Distress Syndrome (ARDS) Treatment Business (2018-2023)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries